XXXX associated with ertapenem use.

@entity1 @entity410 @entity64 @entity4034 @entity149 @entity1833 @entity810 @entity933 @entity6543
OBJECTIVE: To report @entity64 -like symptoms and unusual central nervous system adverse effects in 2 elderly @entity1 receiving ertapenem. CASE SUMMARY: Two @entity1 >= 70 years of age experienced unusual mental status changes while receiving ertapenem. @entity1 1 developed garbled speech and miosis 1 week after starting appropriately dosed @entity6543 (1 g/day) for @entity4034 . Symptoms resolved upon ertapenem discontinuation but recurred upon rechallenge. @entity1 2, a cachectic male with @entity810 , became delirious and progressively obtunded 5 days after starting ertapenem 1 g/day. Nine days after initiation of therapy, he required intubation and mechanical ventilation; ertapenem was discontinued at that time. Within 2 days of ertapenem discontinuation, his mental state cleared and the ventilator was removed. DISCUSSION: Carbapenems, including ertapenem, have been implicated in causing @entity149 , including @entity1833 and @entity410 . However, published reports of other, nonseizure-related central nervous system events are limited. Considerable resources were expended on extensive medical interventions before ertapenem was identified as a potential cause of the @entity933 in our @entity1 . When applied to our @entity1 , the Naranjo probability scale indicated a highly probable relationship for @entity1 1 and a probable relationship for @entity1 2 between the adverse effects and ertapenem use. CONCLUSIONS: Clinicians should be cognizant of ertapenem's potential to induce profound changes in mental status that may mimic other conditions in elderly @entity1 .
